The Roy Calne Award

Previously named the Young Investigator’s Award, the Roy Calne Award is made to the competitive winner of submission of a peer review publication in a recognised academic journal.

The award honours the substantial contribution made by Roy Calne, now retired as Professor of Surgery in Cambridge, to the Surgery and Science of Transplantation.

Roy Calne Award Winner 2024

Jack Beadle

Department of Immunology and Inflammation, Imperial College London

“Application of the Banff Human Organ Transplant Panel to kidney transplant biopsies with features suspicious for antibody-mediated rejection”

The British Transplantation Society Roy Calne Award recognises “a most outstanding contribution published in a peer review journal, as a single paper, in the broad field of transplantation” by a member aged under 40 years.



  • Submission Criteria

    The award will be given to the current member of the Society who has, in the opinion of the judging panel, made the most outstanding contribution published in a peer review journal as a single paper. The member must be the first author of the publication and can be from any professional group.

    The publication must be related to the broad field of transplantation and published in the two years preceding the date of the Annual Meeting of the British Transplantation Society. (For example, papers considered for the March 2024 BTS meeting must have been published in a journal dated between Jan 2022 – Dec 2023).


  • Age

    Candidates for the award must be aged under 40 years on the first day of the Annual Meeting for which the award is being considered.

  • United Kingdom

    The candidate’s work must be original and innovative and have been performed largely or entirely within a recognised Institution in the United Kingdom.

  • Nomination

    Candidates must nominate themselves. In addition, the application must  include a recommendation from the Head of Department where the work was carried out.

  • First Author

    Where two applicants consider themselves to be equal first authors of the work, a separate recommendation for each applicant must be submitted by the Head of Department. Applications must be made using the form (see link below) accompanying these rules.

  • Closing Date

    The closing date for applications is 8th January 2024. One electronic application form and accompanying PDF copy of the paper under consideration must be emailed to the secretariat at AND the General Secretary at by closing at 5.00pm, 8th January 2024.

    Please Note: Only one submission per Author.

  • The Roy Calne Award

    A paper may be entered for the Roy Calne Award on two separate occasions if it satisfies all the above rules. A piece of work which has competed unsuccessfully for the Medawar Medal may be entered for the Roy Calne Award at the following meeting and vice versa. However, the same piece of work cannot win both awards.

  • Judging Panel

    The judging panel will be chaired by the Secretary of the Society and usually consists of at least 4 Members of the Council. The 4 members of the panel will be chosen by the executive to provide a broad area of expertise.

    The executive may, at their discretion, choose members of the panel from outside the Council if this is necessary to obtain the required breadth of expertise. However, no member of the judging panel may have a direct interest in any of the papers submitted for the competition. If the Secretary has such an interest, he or she will nominate a Member of the Council to act as Chairman. The decision of the panel will be final.

  • Prize

    The award will be a certificate and £500. The certificate will include all the authors, their affiliation/institution, and the title and journal reference of the winning paper. The winner will be notified at least 2 weeks prior to the Annual meeting/Congress.

View, download and complete the Roy Calne Award Application Form

View and download the Roy Calne Award Score Sheet

Former Roy Calne Award Winners

› 2023 Joint Winners
Angus Hann
Outcomes of normothermic machine perfusion of liver grafts in repeat liver transplantation (NAPLES initiative)

Emily Thompson
MicroRNA antagonist therapy during normothermic machine perfusion of donor kidneys

› 2022
Oliver Tavabie
A novel microRNA-based prognostic model outperforms standard prognostic models in patients with acetaminophen-induced acute liver failure

› 2021
Jenna R. DiRito
Lysis of cold-storage-induced microvascular obstructions for ex vivo revitalization of marginal human kidneys

› 2020
Zubir Ahmed

Prophylaxis of Wound infections-antibiotics in Renal Donation (POWAR):
A UK Multicentre Double blind Placebo Controlled Randomised Trial

› 2019
Joint Winner

David Nasralla
A Randomized trial of normothermic preservation in liver transplantation

Dr Gemma Banham
Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial

› 2018
Chris Johnston
A structurally distinct TGF-beta mimic from an intestinal helminth parasite potently induces regulatory T cells

› 2017
Jason Ali
Diversity of the CD4 T Cell Alloresponse: The Short and the Long of It

› 2016
Jason Ali
CD8 T-cell recognition of acquired alloantigen promotes acute allograft rejection

› 2015
Michelle Willicombe
Postanastomic Transplant Renal Artery Stenosis: Association with De Nobo Class II Donor Specific Antibodies

› 2014
Kate Milward

Multiple Unit Pooled Umbilical Cord Blood is a Viable Source of Therapeutic Regulatory T Cells.

› 2013
Chris Callaghan
Regulation of Allograft survival by inhibitory FcgRllb signalling.

› 2012

Dominic Summers
Analysis of factors that affect outcome after transplantation of kidneys donated after cardiac death in the UK

› 2011 Joint Winners

Thet Su Win
Donor CD4 T cells contribute to cardiac allograft vasculopathy by providing help for autoantibody production. Circulation: Heart Failure 2009 (2):361-9

Joanna Hester nee Wieckiewicz
In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells

› 2010

Yunchuan Ding
Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of Matrix Metalloproteinase -2 and -9.

› 2009

Manuela Gaspar
Location and time-dependent control of rejection by regulatory T cells culminates in a failure to generate memory T cells.

› 2008
Kathryn Brown

› 2007

No Awards

› 2006

Peng H Tan
Imperial College, London
Creation of tolerogenic human dendritic cells via intracellular CTLA4: a novel strategy with potential in clinical immunosuppression.

› 2005

Mahzuz Karim
Nuffield Dept of Surgery, Oxford
Alloantigen-induced CD25+CD4+ regulatory T cells can develop in vivo from CD25-CD4+ precursors in a thymus-independent process

› 2004
Nicola Monk

Deptartment of Nephrology and Transplantation Guy’s Hospital, London.
Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade

› 2003
Julian R Pratt
Deptartment of Nephrology and Transplantation Guy’s Hospital, London
Local synthesis of complement component C3 regulates acute renal transplant rejection

› 2002

Emma Lovegrove
Dept. Surgery, Cambride
Epitope mapping of indirect T cell response to allogenic class I MHC: sequences shared by donor and recipient MHC may prime T cells that provide help for alloantibody production

› 2001

Nick Jones
Nuffield Dept. Surgery, Oxford
CD40-CD40 ligand- independent activation of CD8 positive T cells can trigger allograft rejection

› 2000

Gavin Pettigrew
Dept. SurgeryCambridge
Indirect T cell allorecognition and allo-antibody mediated rejection of MHC class I disparate heart grafts

› 1999

Sheng Yun
Institute of Child Health, London
Suppression of anti-porcine T-cell immune responses by major histocompatibility complex class II transactivator constructs lacking the amino terminal domain

› 1998

Louise Collins & Lorna Shewring
Institute of Child Health, London
A non-viral vector system for efficient gene transfer to corneal endothelial cells via membrane integrins

› 1997

Wilson Wong
Nuffield Dept. Surgery, Oxford
Pre-transplant administration of a single donor class 1 major histocompatibility complex molecule is sufficient for the indefinite survival of fully allogeneic cardiac allografts

› 1996

David Saitovitch
Nuffield Dept. Surgery, Oxford
Recipient cells expressing single donor MHC locus products can substitute for donor-specific transfusion in the induction of transplantation tolerance when pre-treatment is combined with anti-Cd4 monoclonal antibody

› 1995

Christopher Page
Heart Sciences Centre, Harefield
Human endothelial stimulation of allogenic T cells via a CTLA-4 independent pathway